SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-062990
Filing Date
2022-10-11
Accepted
2022-10-11 07:00:16
Documents
14
Period of Report
2022-10-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea166984-8k_nektarther.htm   iXBRL 8-K 30112
2 ANNOUNCEMENT BY NEKTAR THERAPEUTICS ea166984ex99-1_nektarther.htm EX-99.1 6511
3 ANNOUNCEMENT BY PURETECH HEALTH PLC ea166984ex99-2_nektarther.htm EX-99.2 11019
  Complete submission text file 0001213900-22-062990.txt   225524

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20221011.xsd EX-101.SCH 3221
5 XBRL LABEL FILE nktr-20221011_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE nktr-20221011_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT ea166984-8k_nektarther_htm.xml XML 3489
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 221302276
SIC: 2834 Pharmaceutical Preparations